Lesson plan

erteberel

Erteberel ( , ; former developmental code name LY-500307; also known as selective estrogen receptor beta agonist-1 or SERBA-1) is a synthetic, nonsteroidal estrogen which acts as a selective ERβ agonist and was under development by Eli Lilly for the treatment of schizophrenia. It was specifically under investigation for the treatment of negative symptoms and cognitive impairment associated with the condition. It managed to reach phase II clinical trials for this indication in the United States in 2015. As of 2021 development has been discontinued. Erteberel was also under investigation for the treatment of benign prostatic hyperplasia and reached phase II clinical studies for this use but failed to improve symptoms in men with the condition and development for this indication was discontinued. The drug has also been proposed as a potential novel treatment for glioblastoma. Erteberel has 14-fold binding selectivity for the ERβ over the ERα (K i = 0.19 nM versus 2.68 nM, respectively). However, it shows 32-fold functional selectivity for activation of the ERβ over the ERα (EC 50 = 0.66 nM versus 19.4 nM, respectively). It is roughly a full agonist of both the ERβ and ERα (E max = 101% versus 94%, respectively).…

Back to article

Article summary

Erteberel ( , ; former developmental code name LY-500307; also known as selective estrogen receptor beta agonist-1 or SERBA-1) is a synthetic, nonsteroidal estrogen which acts as a selective ERβ agonist and was under development by Eli Lilly for the treatment of schizophrenia. It was specifically under investigation for the treatment of negative symptoms and cognitive impairment associated with the condition. It managed to reach phase II clinical trials for this indication in the United States in 2015. As of 2021 development has been discontinued. Erteberel was also under investigation for the treatment of benign prostatic hyperplasia and reached phase II clinical studies for this use but failed to improve symptoms in men with the condition and development for this indication was discontinued. The drug has also been proposed as a potential novel treatment for glioblastoma. Erteberel has 14-fold binding selectivity for the ERβ over the ERα (K i = 0.19 nM versus 2.68 nM, respectively). However, it shows 32-fold functional selectivity for activation of the ERβ over the ERα (EC 50 = 0.66 nM versus 19.4 nM, respectively). It is roughly a full agonist of both the ERβ and ERα (E max = 101% versus 94%, respectively).…

Key claims

No claims recorded.

Discussion questions

  1. Summarise the article in your own words. Which single claim would you verify first, and why?
  2. Which claim in this article is most likely to be revised as the sources update? How would you check its current status?
  3. If two sources disagreed about one of these facts, what would you need in order to trust one over the other?

Bibliography

No sources recorded.

Key claims and bibliography are generated from the same tracked claims and sources as the article page.